awmsg logo



tiotropium (Spiriva® Respimat®)


Reference No. 1882

Publication date:
04/12/2018


Appraisal information

tiotropium (Spiriva® Respimat®) 2.5 microgram inhalation solution


Company: Boehringer Ingelheim Ltd
BNF category: Respiratory system
NMG meeting date: 10/10/2018
AWMSG meeting date: 14/11/2018
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2118
Ratification by Welsh Government: 03/12/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Tiotropium (Spiriva® Respimat®) is recommended as an option for use within NHS Wales as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Final Appraisal Recommendation (FAR)
Download